tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Serge Belanger, 353 are a BUY (93.63%), 24 are a HOLD (6.37%).
Analyst Serge Belanger, currently employed at NEEDHAM, carries an average stock price target met ratio of 26.71% that have a potential upside of 52.54% achieved within 188 days.
Serge Belanger’s has documented 738 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ESPR, Esperion Therapeutics at 13-Dec-2024.
Analyst best performing recommendations are on GRAY (GRAYBUG VISION).
The best stock recommendation documented was for KALV (KALVISTA PHARMACEUTICALS) at 1/26/2021. The price target of $32 was fulfilled within 14 days with a profit of $15.65 (95.72%) receiving and performance score of 68.37.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
4 months 12 days ago
(08-Aug-2024)
6/6 (100%)
$3.41 (15.79%)
263
Buy
$66
$23.76 (56.25%)
$71
4 months 12 days ago
(08-Aug-2024)
10/13 (76.92%)
$21.94 (49.80%)
337
Buy
$70
$27.76 (65.72%)
$44
1 years 4 months 25 days ago
(25-Jul-2023)
2/3 (66.67%)
$8.35 (13.54%)
105
Hold
$44
$1.76 (4.17%)
$40
1 years 7 months 3 days ago
(17-May-2023)
5/5 (100%)
$1.03 (2.40%)
86
Buy
$33
$-25.16 (-43.26%)
$24
2 years 9 months 10 days ago
(11-Mar-2022)
3/3 (100%)
$-1.3 (-3.79%)
375
Which stock is Serge Belanger is most bullish on?
Which stock is Serge Belanger is most reserved on?
What Year was the first public recommendation made by Serge Belanger?
